Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386502 | 0.79 | AR (0.32) | TRPM8CYP1A2CYP3A4HRH4ALOX15 | |
| SCHEMBL13058560 | 0.79 | PDE2A (0.36) | TRPM8CYP1A2CYP3A4HRH4ALOX15 | |
| SCHEMBL20285912 | 0.78 | P2RX7 (0.42) | TRPM8CYP1A2CYP3A4HRH4ALOX15 | |
| SCHEMBL21542799 | 0.78 | HRH4 (0.38) | TRPM8CYP1A2CYP3A4HRH4ALOX15 | |
| SCHEMBL30154950 | 0.78 | HRH4 (0.38) | TRPM8CYP1A2CYP3A4HRH4ALOX15 | |
| SCHEMBL25703635 | 0.76 | AAK1 (0.30) | TRPM8 | |
| SCHEMBL22623126 | 0.75 | CYP3A4 (0.38) | LRRK2TRPM8CYP1A2CYP3A4ALOX15 | |
| SCHEMBL21092875 | 0.75 | CYP1A2 (0.38) | CYP1A2CYP3A4HRH4ALOX15TSHR | |
| SCHEMBL4547925 | 0.75 | TRPM8 (0.47) | TRPM8 | |
| SCHEMBL4383164 | 0.75 | SORT1 (0.33) | LRRK2CYP1A2CYP3A4ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629342-B2 | Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | claimed |
| CN-101238128-A | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL MYERS SQUIBB CO (US) | 2008-08-06 | — | — | CN | claimed |
| US-20060287323-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287323-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | LRRK2 3860/4885TRPM8 771/4885CYP1A2 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.